Editorial: Prognostic factors in non-small cell lung cancer

Front Oncol. 2023 Mar 14:13:1174625. doi: 10.3389/fonc.2023.1174625. eCollection 2023.

Mohamed Rahouma^{1

2}, Massimo Baudo^{1

3}, Jun Zhang^{4

5}, Luciano Mutti^{6

7}

¹ Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY, United States.
² Surgical Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
³ Department of Cardiac Surgery, Spedali Civili di Brescia, Brescia, Italy.
⁴ Division of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, United States.
⁵ Department of Cancer Biology, University of Kansas Medical Center, Kansas City, KS, United States.
⁶ Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, United States.
⁷ Department of Applied Clinical Sciences and Biotechnology, L'Aquila University, L'Aquila, Italy.

No abstract available

Keywords: immune checkpoint inhibitors; immunotherapy; lung cancer; noncoding RNA; prognosis; survival.

Publication types